Epidermal growth factor receptor (EGFR) domain III (EGFR Domain III)

Epidermal growth factor receptor (EGFR) domain III is a specific structural region within the extracellular portion of the EGFR protein, a member of the ErbB family of receptor tyrosine kinases (UniProt: P00533). This domain plays a pivotal role in cellular signaling by serving as the primary binding site for ligands such as epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-alpha) (PubMed: 15752753). Binding of these ligands to Domain III induces a conformational shift that transitions the receptor from an inactive tethered state to an active extended state, allowing for receptor dimerization and activation of intracellular kinase domains (PubMed: 12297050). In various malignancies, including colorectal and head and neck cancers, EGFR is often overexpressed or constitutively active, driving tumor progression and resistance to apoptosis (PubMed: 15592450). Therapeutic strategies targeting Domain III primarily involve monoclonal antibodies like Cetuximab and Panitumumab, which sterically block ligand access and prevent the receptor's transition to its signaling-competent form (PubMed: 16432177). Clinical challenges include the development of acquired resistance through specific mutations within Domain III, such as S492R, which can disrupt antibody binding while preserving receptor function (PubMed: 22266346).

Other names

ErbB1 domain IIIHER1 domain IIIEGFR extracellular domain IIIEGFR-ECD domain IIIEGFR L2 domain

Monoclonal antibodies bind to Domain III of the EGFR extracellular region, competitively inhibiting the binding of endogenous ligands like EGF and TGF-alpha (PubMed: 15752753). This prevents the receptor from transitioning to its active, extended conformation, thereby inhibiting dimerization, autophosphorylation, and downstream signaling pathways such as RAS/MAPK and PI3K/AKT (PubMed: 16432177). Additionally, some antibodies like Cetuximab can induce antibody-dependent cellular cytotoxicity (ADCC) (PubMed: 18566223).